Midline catheters, inserted peripherally but extending further into the vasculature than a standard short peripheral IV without reaching central venous position, continue gaining adoption as a lower-risk alternative to PICC lines for patients whose treatment duration and infusate characteristics don't actually require true central venous access.
Why the Distinction Matters
PICC lines, while valuable for their intended use cases, carry meaningfully higher complication risk — including deep vein thrombosis and catheter-related bloodstream infection — than midline catheters, and evidence has increasingly shown a substantial share of PICC placements historically occurred in patients who could have been appropriately managed with the lower-risk midline option instead.
Building an Appropriate Selection Framework
- Treatment duration — midlines are generally appropriate for shorter courses, typically under one to four weeks depending on institutional protocol, while longer courses may still favor PICC placement
- Infusate characteristics — vesicant medications, certain high-osmolarity solutions, and parenteral nutrition typically still require true central access rather than a midline
- Formal vascular access selection tools, increasingly built into clinical decision support, help standardize this determination rather than leaving it to inconsistent individual clinician judgment
The Resulting Supply Chain Shift
As midline adoption grows for appropriate use cases, facilities are seeing a meaningful shift in vascular access device mix, with implications for both supply cost — midlines are generally less expensive than PICCs — and for vascular access team staffing needs, since midline insertion typically requires less specialized skill than central line placement.
Facilities building vascular access selection protocols can review Healix Medical Supply's IV and vascular access catalog.
